Surgical Robotics Company Vicarious Surgical To Merge With D8 SPAC In $1.1Bn Deal
Vicarious Surgical, whose medical robot received US FDA breakthrough designation, announced it will merge with D8 Holdings Corp. The deal is expected to garner up to $460m.
You may also be interested in...
Medtech Insight interviewed the CEO of Ceros Financial Services and its investment banking division, Ceros Capital Markets, about the firm’s considerations for funding early-stage medtechs, and outlook for medtech fundraising, in this uncertain economic climate.
The company originally expected the first-in-human trial of the soft-tissue robotic surgery system to begin in late 2022 and reach the market by 2023, but the company now expects those trials to begin in 2024.
During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.